14.1 Indications for Transfusion
Key Takeaways
- Restrictive RBC transfusion strategies (trigger near Hb 7 g/dL for most stable adults) are noninferior to liberal strategies per TRICC, TRISS, and FOCUS; a fixed number should never override active bleeding or symptomatic instability.
- Prophylactic platelet transfusion is generally reserved for counts below 10 x10^9/L in stable hypoproliferative thrombocytopenia, with higher thresholds (20-30, 50, or 100 x10^9/L) for procedures, active bleeding, or CNS/ocular risk.
- Plasma corrects multiple coagulation factor deficiencies with bleeding or an invasive procedure; it is never appropriate as an isolated volume expander or to correct an elevated INR with no bleeding risk.
- Sickle cell disease with acute chest syndrome, stroke, or preoperative HbS reduction is managed with red cell exchange (erythrocytapheresis) targeting HbS below roughly 30%, not simple transfusion alone.
- Massive transfusion protocols activate on physiologic instability and predicted need, not a single lab value, and use ratio-based (near 1:1:1 RBC:plasma:platelet) component support until viscoelastic testing can guide targeted replacement.
Why indications questions are different at the specialist level
At the generalist level, transfusion indication questions often reduce to "the hemoglobin is low, so transfuse." The SBB exam expects more: it tests whether you know the evidence base behind current thresholds, when a disease-specific exception overrides the general rule, and when the correct answer is to withhold a component rather than release it. Indications for transfusion sit inside ASCP Transfusion Practice content area V.A, and the exam pairs this reasoning with component selection (V.B) and administration/PBM (V.E) in the same case-based question.
Evidence-based RBC transfusion thresholds
Large randomized trials changed practice from a fixed "10/30" rule (hemoglobin 10 g/dL, hematocrit 30%) to individualized restrictive thresholds.
| Trial/guideline | Population | Restrictive trigger tested | Result |
|---|---|---|---|
| TRICC (1999) | Critically ill ICU patients | Hb <=7 g/dL vs <=10 g/dL | Restrictive strategy was as safe or safer; abandoned the routine 10/30 rule |
| FOCUS (2011) | Older adults after hip fracture surgery with cardiovascular risk | Hb <=8 g/dL vs symptomatic liberal trigger | No difference in mortality or functional outcome; restrictive strategy supported |
| TRISS (2014) | Septic shock | Hb <=7 g/dL vs <=9 g/dL | No mortality benefit from the liberal threshold |
| AABB clinical practice guideline | General hospitalized adults, hemodynamically stable | Hb 7-8 g/dL | Restrictive strategy is the default; higher threshold reserved for specific risk |
The practical exam rule: for a stable, non-bleeding adult, do not transfuse until hemoglobin falls to roughly 7 g/dL, or roughly 8 g/dL for patients with significant cardiovascular disease or active myocardial ischemia, where impaired oxygen delivery carries higher risk. Symptoms of anemia (chest pain, dyspnea, orthostatic hypotension, tachycardia unresponsive to volume) can justify transfusion above the numeric trigger; the number is a floor, not a mandate. Active hemorrhage or hemodynamic instability is managed by clinical response, not a static hemoglobin value at all.
Platelet transfusion criteria
Platelet thresholds scale with bleeding risk, not a single universal number.
| Clinical scenario | Typical trigger | Rationale |
|---|---|---|
| Stable hypoproliferative thrombocytopenia, no bleeding, no procedure | <10 x10^9/L | Spontaneous hemorrhage risk rises sharply below this level |
| Central line placement, bone marrow biopsy, lumbar puncture | <20-30 x10^9/L (institution-specific) | Lower bleeding risk than major surgery |
| Major surgery | <50 x10^9/L | Balances surgical hemostasis against transfusion burden |
| Neurosurgery or ophthalmic surgery | <100 x10^9/L | Even minor bleeding in a closed space is high-consequence |
| Active bleeding, DIC, or qualitative platelet dysfunction with hemorrhage | Individualized, often <50 x10^9/L (higher for CNS/ocular bleeding) | Function matters as much as count |
Antiplatelet drug effect or uremic platelet dysfunction can justify transfusion even with a normal count when there is significant bleeding.
Plasma and cryoprecipitate indications
Plasma replaces multiple coagulation factors simultaneously. Appropriate indications include active bleeding or a planned invasive procedure in a patient with a significant coagulopathy from multiple factor deficiency (liver disease, dilutional coagulopathy, massive transfusion), and urgent warfarin reversal when prothrombin complex concentrate is unavailable or contraindicated. Plasma is not appropriate as a volume expander and is not indicated to correct an elevated INR in a patient who is not bleeding and has no imminent procedure — this is a classic exam trap.
Cryoprecipitate concentrates fibrinogen, factor VIII, von Willebrand factor, and factor XIII. Its primary current indication is hypofibrinogenemia with bleeding (fibrinogen typically <100-150 mg/dL), seen in obstetric hemorrhage, DIC, liver disease, and massive transfusion. Factor-specific concentrates have largely replaced cryoprecipitate for isolated factor VIII, von Willebrand disease, or hemophilia management where available.
Massive transfusion: activation and approach
A massive transfusion protocol (MTP) activates based on physiologic instability and predicted need — for example, ongoing hemorrhage with hypotension, or an anticipated requirement of four or more RBC units within an hour, or ten units within 24 hours — not a single fixed hemoglobin trigger. Early MTP management favors ratio-based component support, commonly near 1:1:1 (RBC:plasma:platelet), which approximates reconstituted whole blood and limits dilutional coagulopathy. As viscoelastic testing (TEG or ROTEM) results become available, therapy shifts to goal-directed, lab-guided replacement. Adjuncts include tranexamic acid (most effective within three hours of traumatic injury), calcium repletion (citrate in large-volume transfusion chelates ionized calcium), avoiding excess crystalloid, and permissive hypotension in trauma before definitive hemorrhage control to avoid "popping the clot" and worsening dilutional coagulopathy.
Specialty populations
Neonates. Small blood volume changes have large physiologic effects, so aliquots are dosed by weight (typically 10-15 mL/kg) from fresh, irradiated, CMV-safe units. Transfusion thresholds vary by postnatal age, weight, and respiratory support rather than a single adult-style number, and exchange transfusion is reserved for severe hemolytic disease of the fetus and newborn or dangerous hyperbilirubinemia.
Sickle cell disease. Simple transfusion treats symptomatic anemia or aplastic crisis, but acute chest syndrome, stroke, and preoperative optimization call for red cell exchange (manual or automated erythrocytapheresis) that reduces HbS to roughly below 30% while avoiding the hyperviscosity that simple top-up transfusion can cause by raising the hematocrit too high. Because this population has elevated alloimmunization risk, extended antigen-matched (commonly Rh and K, sometimes broader) units are preferred, and unnecessary transfusion is avoided given the long-term risk of iron overload.
Oncology/hematology. Prophylactic platelet transfusion at <10 x10^9/L in stable patients is supported by trial evidence (e.g., TOPPS), with higher thresholds during fever, infection, or rapidly falling counts. Irradiated components are required for patients undergoing or recovering from hematopoietic stem cell transplant or receiving purine-analog chemotherapy, to prevent transfusion-associated graft-versus-host disease.
A hemodynamically stable, non-bleeding hospitalized patient with no cardiac disease has a hemoglobin of 7.2 g/dL. Per restrictive transfusion evidence such as TRICC, what is the most appropriate action?
Which patient most clearly justifies a higher RBC transfusion threshold (closer to 8 g/dL) than the general restrictive trigger?
A patient with sickle cell disease presents with acute chest syndrome and worsening hypoxia. Which transfusion approach best reduces HbS quickly while avoiding hyperviscosity?
Which statements correctly describe a modern massive transfusion protocol (MTP)? Select all that apply.
Select all that apply